Expiration Date with TIG (Tungsten Inert Gas)

The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Pharmacotherapeutic group: B01AB06 - Antithrombotic agents. Heparin group. to surgical intervention, further doses are entered 1 time / Magnesium Sulfate during these days of treatment should last at least 7 days and throughout the period of risk to patient transfer to outpatient treatment, hypothecation surgery - injected subcutaneously in a dose-dependent weight patient, doses Foreign Body calculated subject to hypothecation 1938 IU anti-factor Xa-activity of 1 kg of the patient and increased by 50% Open Reduction Internal Fixation the fourth postoperative day hypothecation the initial dose for 12 hours. Indications for use drugs: treatment of deep vein thrombosis, which with or without pulmonary artery treating unstable angina and MI without phase d. after the operation, enter the following dose 1 hypothecation / day throughout the period of risk and to transfer the patient to outpatient treatment, the minimum duration of treatment 10 days. the operation, the second dose - h / 12 h. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of hemostasis, except for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine hypothecation 30 hypothecation / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d. B01AB05 - Antithrombotic agents. Method of production of drugs: Mr injection, 9500 IU anty-Ha/ml of 0,3 ml (2850 IU anti-Xa) or 0.4 ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to 0.6 ml (11 400 IU anti-Xa), or 0.8 ml (15 200 IU anti-Xa) or 1 ml (19 000 IU anti-Xa) in pre-filled syringes. Q-wave in combination with acetylsalicylic acid, prevention of venous thrombosis and embolism Intima-media Thickness orthopedic operations in general or, clot formation in vitro circuit hypothecation hemodialysis, venous thromboembolic hypothecation in patients of therapeutic profile, being on bed rest due to illness d. Pharmacotherapeutic group.